Rebiotix

Join the Battle to Defeat C. diff Infection

PUNCH CD3-OLS is a clinical study to evaluate the safety and tolerability of Rebiotix RBX2660 for the prevention of recurrent Clostridium difficile infection (C. diff or CDI). With this study option, many more people that suffer from recurrent C. diff may now qualify for study participation.

Study patients receive expert medical care and specialized attention from the study team. The cost of the study drug, study-related tests, as well as study follow-up calls and visits will be covered by the study  sponsor, Rebiotix. 

If you or someone you know has a C. diff infection, contact us to learn more. With your help, we can put a stop to this deadly disease.

For more information or eligibility criteria, call our Research Hotline number at 612-870-5599, OR input the following information and we will follow up with you to discuss your interest:

 

ATTENTION: This form is for information only and does not guarantee participation in any study. This form is also not meant for transmitting medical, prescription or appointment information or to initiate direct communications with our health care providers. Those inquiries should be sent through the Patient Portal or you can contact us at (612) 871-1145. Web form submissions are monitored Monday through Friday during regular business hours. In the event of a medical emergency, please dial 911.